Close Menu

Europe

In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.

FIND will use the funding to support the development of rapid tests, especially in low- and middle-income countries.

University of Oxford researchers said they are weeks away from completing clinical validation of a coronavirus molecular test based on RT-LAMP technology.

Profiling microbial communities in cervicovaginal samples from women carrying high-risk HPV strains, researchers found possible markers of pre-cancer progression.

Alterations that arise that have high fitness are also associated with an increased risk of developing acute myeloid leukemia.

Investigators worldwide are sharing data to search for features in the human genome that might contribute to COVID-19 susceptibility or progression.

The test, which uses an Applied Bioystems TaqPath assay and real-time PCR technology, detects nucleic acid from SARS-CoV-2, the virus that causes COVID-19.

Biocartis will lead commercialization in Europe as the exclusive distributor of the SeptiCyte Rapid test, while Immunexpress will lead commercialization of the test in the US.

Now, the assay can also be used with the Applied Biosystems 7500 Standard from Thermo Fisher Scientific, Roche's LightCycler 480, and Qiagen's Rotor-Gene Q.

Still Following It

Bloomberg writes that Fred Hutchinson Cancer Research Center's Trevor Bedford and his colleagues continue to use viral genomics to track SARS-CoV-2.

Pages

Researchers in India plan to sequence SARS-CoV-2 isolates from around the country, according to LiveMint.

Mauro Ferrari has resigned as president of the European Research Council over its response to the COVID-19 pandemic, the Financial Times reports.

Stat News reports some health tech startups are laying off or furloughing workers.

In Genome Research this week: indels affecting microsatellites in cancer, analytical approach to find key regulatory elements, and more.